JERUSALEM, October 16, 2025 — Leads & Copy — Entera Bio Ltd. (NASDAQ: ENTX) will present new clinical data from its Phase 2 trial of EB613 at the upcoming North American Menopause Society (NAMS) 2025 Annual Meeting in Orlando, Florida, October 21–25, 2025. The presentation will showcase Phase 2 data from EB613 in early postmenopausal women with low bone mass or osteoporosis, examining bone mineral density outcomes over six months.
Miranda Toledano, Chief Executive Officer of Entera, said that anabolic therapies are underutilized despite their proven ability to rebuild bone. Toledano said EB613 has the potential to move treatment earlier in the care continuum and broaden access for the over 200 million women worldwide living with osteoporosis.
EB613 (oral PTH (1-34)), is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
Ms. Miranda Toledano
Chief Executive Officer, Entera Bio
Email: miranda@enterabio.com
Source: Entera Bio
